Comparative Pharmacology
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE INTENSOL versus NAQUA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE INTENSOL versus NAQUA.
HYDROCHLOROTHIAZIDE INTENSOL vs NAQUA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and chloride reabsorption and increasing water excretion.
Inhibition of sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis.
25-100 mg orally once daily or in divided doses. Titrate based on response; maximum 200 mg/day.
Oral: 5-10 mg once daily, preferably in the morning. Maximum dose 20 mg/day.
None Documented
None Documented
Terminal half-life 6–15 hours (mean ~10 hours); prolonged in renal impairment (creatinine clearance <30 mL/min) and elderly.
Terminal elimination half-life is 6-12 hours; prolonged in renal impairment (up to 20-30 hours) or heart failure due to reduced renal perfusion.
Primarily renal (≥95% as unchanged drug); negligible biliary/fecal elimination (<5%).
Primarily renal elimination; approximately 60-80% excreted unchanged in urine via tubular secretion; minor biliary/fecal excretion (<10%).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic